Clinical Takeaway
Trauma-focused treatments remain effective for PTSD even in patients who use cannabis, including those with co-occurring substance use disorders. Clinicians should not withhold or delay evidence-based PTSD care based on a patient’s cannabis use status.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis addresses a critical clinical gap by providing evidence on whether trauma-focused treatments maintain efficacy in patients with comorbid PTSD and substance use disorders who also use cannabis, a population often excluded from or underrepresented in treatment trials. The findings directly inform treatment selection and prognostication for the substantial proportion of PTSD+SUD patients presenting with concurrent cannabis use in clinical practice. Understanding treatment outcomes across cannabis use status helps clarify whether clinicians should modify evidence-based protocols or manage cannabis use separately when treating complex comorbidity.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this meta-analysis addresses a clinically important question about trauma-focused treatment outcomes in patients with concurrent cannabis and other substance use, several limitations warrant careful interpretation: the analysis draws from only four of 36 available RCTs, potentially introducing selection bias, and the abstract does not specify whether cannabis use was measured objectively or by self-report, which affects confidence in exposure classification. The heterogeneity of “cannabis use” as a variable—ranging from occasional to heavy, from smoked to edible formulations—likely obscures clinically meaningful subgroups, and we cannot determine from this summary whether baseline cannabis use, concurrent use during treatment, or both were examined. For clinical practice, the key takeaway is that clinicians should not reflexively assume cannabis use invalidates evidence-based trauma-focused therapy; however, patients should be counseled that active cannabis use during treatment may complicate symptom assessment and adherence, and baseline substance use patterns should inform individualized treatment planning and intensity of monitoring.